Seagate’s spending put it in 126th place out of the top 2,500 companies in the world in the annual survey by the European Commission. Photograph: Paul Faith/PA Wire

A survey has found that Seagate Technology, an American data storage company, is the single biggest investor in research and development (R&D) in(...)

Botox is one of a number of pharmaceutical products made in Allergan’s Westport plant. Photograph: Shannon Stapleton/Files/Reuters

Allergan, the maker of Botox, has agreed to sell itself in a $66 billion (€53 billion) deal with fellow drugs group Actavis, with rival Valeant bowing(...)

A doctor injects a patient with Allergan’s Botox. Photographer: Patrick T. Fallon/Bloomberg

Botox maker Allergan, which is fending off an acquisition by Valeant Pharmaceuticals, said today that it had been approached by another party regardi(...)

Pfizer has yet to formally put a value on the Actavis bid as it says no actual offer has been made, but it does make for a complicated chain all the same.

Keeping track of the merry-go-round that is pharma M&A is quite a challenge. It’s not all down to corporate inversion – that bête noir of US polit(...)

 Pfizer has approached Actavis to express its interest in an acquisition that could allow the US drugmaker to move overseas and reduce taxes. Photo: Bloomberg

Ireland is back at the centre of the controversy over corporate inversion as it emerged that drug giant Pfizer has approached Irish-headquartered Acta(...)

M&A activity in Ireland is at its strongest since 2008 with 42 deals announced during the first half of the year, according to new figures compile(...)

The head offices of Valeant Pharmaceuticals  in Laval, Quebec. The Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile in the battle for control of its US rival. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53 billion offer was rejected by the mak(...)

Pfizer’s plan to move its domicile to Britain by acquiring AstraZeneca would lower its taxes. Photograph: getty images

Rumours about a massive healthcare deal were circulating in industry circles, months before Pfizer disclosed its $100 billion pursuit of Britain’s Ast(...)

The pace of acquisition at the formerly stolid generics player has been bewildering in the 22 months since Watson acquired Actavis.

As the dust settles on Actavis’s latest megamerger, the Dublin-headquartered but US-based group managed to win its first post-M&A battle – (...)

Ryanair repurchased 109,000 shares yesterday as part of its plans to return €1 billion in capital to shareholders by way of a combination of share buybacks and dividends.  Photograph: Rui Vieira/PA Wire

US stocks fluctuated, with the Standard & Poor’s 500 Index close to a record, as a $25 billion deal to acquire Forest Labo(...)